Clinical Trials

For more information about clincial trials for the patients with neurological diseases, see: http://www.clinicaltrials.gov

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
PURPOSE: This randomized phase II trial is studying temozolomide, radiation therapy, and cediranib maleate to see how well they work compared with temozolomide, radiation therapy, and a placebo in treating patients with newly diagnosed glioblastoma. Learn more
Contact: Maciej Mrugala, MD, University of Washington, Seattle, WA, T 206-598-4127; or John W. Henson, MD, FAAN, Swedish Neuroscience Institute, Seattle, WA T (206) 320-8297. (11/30/11)

Double-blind, randomized, historical control study of the safety and efficacy of eslicarbazepine acetate monotherapy in subjects with partial epilepsy
This is an RCT comparing 1200 mg to 1600 mg of eslicarbazepine in monotherapy to historical control patients in prior FDA-approved monotherapy studies. Subjects aged 16-70 years with focal onset epilepsy and seizures with observable clinical signs taking 1-2 marketed epilepsy drugs are eligible. Learn more. Contact: David Vossler, MD, UW Medicine | Valley Medical Center, and Connie Baum, Rainier Clinical Research Center, 425-251-1720 (11/28/2011)

NovoCure: EF-14 TTF Device Upfront for Newly Diagnosed GBM
A prospective, multi-center trial of NovoTTF-100A (NovoCure) device together with temozolomide compared to temozolomide alone (after RT/TMZ) in patients with newly diagnosed GBM. Learn more. Contact: John W. Henson, MD, FAAN, Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA T (206) 320-8297
Posted (5/13/2010)

High-Dose Methotrexate and Liposomal Cytarabine in Treating Patients With Central Nervous System (CNS) Metastases From Breast Cancer
This study is currently recruiting participants. Learn more
Verified by Fred Hutchinson Cancer Research Center, February 2010 (03/17/10)

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures (ALEX-MT)
The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to lacosamide monotherapy in subjects with partial-onset seizures who are withdrawn from 1 to 2 marketed antiepileptic drugs. Learn more
Contact: David Vossler, MD, Washington Neuroscience Institute, Renton, WA T (425) 656-5566
Posted (3/2/2010)

Clinical trials are a critical method by which therapies for neurological illnesses are advanced. Many neurological trials in the United States are greatly hampered by insufficient recruitment of subjects, and thus, awareness of trials by patients and providers is a major contributor to recruitment. Therefore, the WSNS attempts to increase provider awareness of clinical trials by posting them on its website. There will be no fee for posting a clinical trial.

Trials proposed for listing on the website must also meet the following standards:

-Submitted in the format of trialscurrently listed on the WSNS web site 
-WSNS member submitting the trial as study contact (rather than an institutional representative)
-Up-to-date notification of changes in study status by WSNS member posting the study. Studies will be reviewed by WSNS staff every 6 month to ensure active status
-Approval by an accepted local or national Institutional Review Board (IRB)
-Active recruitment of study subjects
-Study is listed on http://www.clinicaltrials.gov
-WSNS Web Trials subcommittee review and approval completed.